07. 07. 2022

Constructing a digital twin for Cytokine Release Syndrome patients following CAR-T therapy

This year marked Phesi’s first attendance as an exhibitor at ASCO, the annual meeting of professionals and exhibitors, held by the American Society of Clinical Oncology. At the event, we announced the news that Phesi has created a new digital twin for Cytokine Release Syndrome (CRS) patients following Chimeric Antigen Receptor (CAR)-T therapy, based on our analysis of 5,473 CAR-T treated patients. The news opened up some insightful conversations at the event and has created opportunities to fundamentally transform clinical research.

Read more
05. 25. 2022

Participants in breast cancer clinical trials are getting younger. What does this mean for the future of clinical trial design?

This month, Phesi’s data revealed some fundamental insights into the changing landscape of clinical trials. Our analysis of more than 2.5 million breast cancer patients found that since 2014, the number of women younger than 60 years of age participating in clinical trials has increased dramatically, from 30% to 90%. Our analysis has paved the way for some well overdue conversations about patient centricity in clinical trials as we reflect on what this finding means for trial sponsors.

Read more
04. 28. 2022

Why do nine out of ten clinical trials fail, and how can the industry learn from these mistakes?

Clinical trials are notoriously expensive, time-consuming, and often face huge setbacks. In fact, a recent report from the American Society for Biochemistry and Molecular Biology found that as many as 90% of drugs that make it to clinical trial ultimately fail – which is frustrating for sponsors, regulators, and patients.

A successful clinical trial starts at the design stage: rigorously designed and implemented clinical trials are at the heart of delivering innovative new treatments to patients. But how can the clinical development community overcome issues in planning and design trials that deliver results?

Read more
04. 01. 2022

What steps can clinical development organizations take to mitigate the risks after the war in Ukraine?

We all hope that the war in Ukraine will end as soon as possible, but there is no denying that its impact will be long-lasting. The clinical development industry in particular will take some time to recover. Although the war is happening in a single country, the effect on clinical development is global. What can sponsors do to keep the development of new treatments moving forward?

Read more
03. 02. 2022

Phesi’s reflections of SCOPE 2022

The SCOPE Summit in Orlando, Florida was a hybrid event this year with many people attending in-person, including the Phesi team. It was great to see some familiar faces from the clinical development community without having to shout, “you’re on mute!” through our computer screens. As with every year, the event saw new connections made, thought-provoking breakout sessions, and much buzz surrounding exciting innovations in the clinical trial space.

Read more